EU regulator green lights an injectable HIV drug that could help stop transmission - Health - Life & Style
In a statement the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein.
Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men.
Winnie Byanyima, executive director of the U.N. AIDS agency, has said the drug 'could change the trajectory of the HIV epidemic' if it is made available to everyone who needs it.
In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus.
Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills.
Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean.
But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease.
Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS.
UNAIDS chief Byanyima has previously suggested that President Donald Trump make a deal with Gilead to produce and license its 'magical' prevention drug lenacapavir across the world to the millions of people who need it.
Follow us on:
Short link:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
18 hours ago
- Mid East Info
Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth - Middle East Business News and Information
Dubai, United Arab Emirates;July 2025 — Millions of people are affected by chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands. While chemotherapy and radiation treatment for head and neck cancer are the most common causes of this, aging, certain medications and other factors, including diabetes, stroke, Alzheimer's disease and HIV/AIDS, can also cause chronic dry mouth. Currently, there is no cure for it. Mayo Clinic researchers have established the world's first biobank of human salivary gland tissue-organoids that opens the door to research to find a cure. 'This unique biobank resource overcomes a major barrier we've faced in the field, namely: limited access to standardized salivary specimens suited for salivary gland regeneration research. This collection provides a foundation for regenerative therapy development, especially for radiation-induced chronic dry mouth,' says Nagarajan Kannan, Ph.D., lead author of the study published in NPJ Regenerative Medicine. Dr. Kannan is also the director of the Mayo Clinic Stem Cell and Cancer Biology Laboratory. Nearly 70% of patients with head and neck cancer who are undergoing radiation therapy experience permanent damage to their salivary glands. People with this condition experience diminished quality of life from a constant feeling like cotton is lining their mouths. Besides being uncomfortable, chronic dry mouth can lead to difficulties with chewing, tasting, speaking and swallowing. It also can cause tooth decay. 'Chronic dry mouth can extend long after radiation treatments are complete. It's among the top concerns I hear from patients with head and neck cancer. Unfortunately, there aren't many therapeutics available commercially for these patients,' says co-author Jeffrey Janus, M.D., an ear, nose and throat specialist at Mayo Clinic in Florida. One promising avenue of research is the cultivation of rare regenerative cells to greater numbers that can help people someday heal and grow new, healthy salivary gland cells. The biobank consists of specimens collected from 208 donors. From this repository, researchers have already found biomarkers for mature, saliva-producing cells, and with the help of a high-resolution protein map, they have identified the potential tissue origin of rare, self-renewing salivary cells. The research team also developed a radiation injury model, which paired with the biobank, provides an integrated platform to discover new, personalized regenerative biotherapeutics. This is a collaboration between Mayo Clinic Center for Regenerative Biotherapeutics, Department of Laboratory Medicine and Pathology and Department of Otolaryngology.
Al-Ahram Weekly
3 days ago
- Al-Ahram Weekly
EU regulator green lights an injectable HIV drug that could help stop transmission - Health - Life & Style
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein. Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men. Winnie Byanyima, executive director of the U.N. AIDS agency, has said the drug 'could change the trajectory of the HIV epidemic' if it is made available to everyone who needs it. In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus. Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills. Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean. But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease. Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS. UNAIDS chief Byanyima has previously suggested that President Donald Trump make a deal with Gilead to produce and license its 'magical' prevention drug lenacapavir across the world to the millions of people who need it. Follow us on: Facebook Instagram Whatsapp Short link:
Daily News Egypt
5 days ago
- Daily News Egypt
Zimbabwe Faces Resurgence of Malaria Amid U.S. Aid Cuts, Experts Warn of Funding Shortfall
Zimbabwe is grappling with a sharp resurgence of malaria following a significant drop in international aid, particularly after the withdrawal of U.S. funding. Health experts have raised the alarm, citing a dramatic increase in infections and fatalities across the country in 2025, with fears that ongoing national response efforts could be severely undermined. According to the Ministry of Health, the number of malaria infections surged by 180% in the first four months of 2025, while related deaths jumped by 218% compared to the same period last year. Over 119,000 cases were reported between January and June, with at least 143 fatalities, up from 45 during the same period in 2024. Health officials reported the emergence of 115 malaria outbreak hotspots this year—an alarming contrast to just one outbreak recorded in all of 2024. Impact of U.S. Funding Withdrawal The resurgence coincides with the suspension of key U.S. financial assistance under a policy shift initiated by former President Donald Trump, who earlier this year halted funding for several global health programmes, including malaria and HIV/AIDS initiatives. Experts say the funding cut has disrupted critical scientific research, interrupted mosquito control programmes, and delayed national malaria prevention campaigns. The absence of U.S. support is also affecting basic prevention tools such as insecticide-treated mosquito nets and essential medicines. 'It's a serious setback,' said Itai Rusike, director of the Community Working Group on Health at Zimbabwe's Ministry of Health. 'The country had made tremendous progress over the past two decades, but all of that is now at risk.' Rusike warned that without adequate supplies of mosquito nets and preventive drugs, especially for pregnant women and young children, the number of infections and fatalities will likely continue to climb. 'Lives will be lost. When diagnostic kits and frontline treatments are unavailable, the system collapses,' he added. Shortage of Nets and Medical Supplies In May, the Ministry of Health launched a campaign to distribute over 1.6 million insecticide-treated mosquito nets. However, officials acknowledged a shortfall of at least 600,000 nets due to the funding freeze. This gap is particularly concerning given that bed nets remain one of the most cost-effective tools in malaria prevention. Children under the age of 15 account for a significant proportion of the affected population, representing nearly 14% of all reported cases, according to government data. Road to 2030: Struggling to Stay on Track Zimbabwe is among several African Union member states committed to eliminating malaria by 2030. The country's national strategy includes increasing public awareness, widespread distribution of treated mosquito nets, indoor spraying, and enhancing surveillance systems. However, health officials admit the funding shortfall has disrupted the roadmap toward malaria eradication. Former Health Minister Dr. Henry Madzorera stressed the need for mobilising domestic resources, saying Zimbabwe must rely less on external donors. 'We need to increase health sector allocations, use existing tax revenues more efficiently, and prioritise domestic financing to safeguard our health goals,' he said. Deputy Health Minister Sleiman Kudini also acknowledged the funding gap, adding that the government is making efforts to procure essential supplies. 'We've started the process of purchasing critical items and remain committed to the 2030 malaria elimination target,' Kudini said. Despite government assurances, experts caution that unless sustainable funding mechanisms are secured quickly, the country risks reversing years of progress in malaria control.
